INTERVENTION 1:	Intervention	0
Arm A: FAC	Intervention	1
FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv	Intervention	2
5-fluorouracil	CHEBI:46345	5-19
5-fluorouracil	CHEBI:46345	53-67
doxorubicin	CHEBI:28748,BAO:0000639	21-32
doxorubicin	CHEBI:28748,BAO:0000639	125-136
cyclophosphamide	CHEBI:4026	34-50
cyclophosphamide	CHEBI:4026	153-169
day	UO:0000033	84-87
5-fluorouracil	Intervention	3
5-fluorouracil	CHEBI:46345	0-14
Doxorubicin	Intervention	4
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Intervention	5
cyclophosphamide	CHEBI:4026	0-16
INTERVENTION 2:	Intervention	6
Arm B: TAC	Intervention	7
TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv	Intervention	8
doxorubicin	CHEBI:28748,BAO:0000639	16-27
doxorubicin	CHEBI:28748,BAO:0000639	114-125
cyclophosphamide	CHEBI:4026	29-45
cyclophosphamide	CHEBI:4026	142-158
day	UO:0000033	73-76
Docetaxel	Intervention	9
Doxorubicin	Intervention	10
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Intervention	11
cyclophosphamide	CHEBI:4026	0-16
Inclusion Criteria:	Eligibility	0
Written informed consent	Eligibility	1
Operable breast cancer patients (T1-T3) with negative axillary lymph nodes (10 axillary nodes dissection) and high risk criteria according to St. Gallen consensus criteria.	Eligibility	2
breast cancer	DOID:1612	9-22
lymph	UBERON:0002391	63-68
Histologically proven breast cancer. Interval between surgery and registration is less than 60 days.	Eligibility	3
breast cancer	DOID:1612	22-35
surgery	OAE:0000067	54-61
Definitive surgical treatment must be either mastectomy, or breast conservative surgery. Margins of resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ is not considered as positive margin.	Eligibility	4
breast	UBERON:0000310	60-66
surgery	OAE:0000067	80-87
surgery	OAE:0000067	123-130
adenocarcinoma	DOID:299	171-185
carcinoma	HP:0030731,DOID:305	176-185
carcinoma	HP:0030731,DOID:305	197-206
carcinoma	HP:0030731,DOID:305	231-240
Patients without proven metastatic disease.	Eligibility	5
disease	DOID:4,OGMS:0000031	35-42
Estrogen and progesterone receptors performed on the primary tumour prior to randomization.	Eligibility	6
estrogen	CHEBI:50114,BAO:0000760	0-8
progesterone	CHEBI:17026	13-25
Age between 18 years and 70 years.	Eligibility	7
age	PATO:0000011	0-3
Karnofsky performance status index > 80 %.	Eligibility	8
Adequate hepatic, renal and heart functions.	Eligibility	9
heart	UBERON:0000948	28-33
Adequate hematology levels.	Eligibility	10
Negative pregnancy test	Eligibility	11
Exclusion Criteria:	Eligibility	12
Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).	Eligibility	13
breast cancer	DOID:1612	38-51
Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.	Eligibility	14
anthracycline	CHEBI:48120	6-19
paclitaxel	CHEBI:45863	40-50
Prior radiation therapy for breast cancer.	Eligibility	15
breast cancer	DOID:1612	28-41
Bilateral invasive breast cancer.	Eligibility	16
bilateral	HP:0012832	0-9
breast cancer	DOID:1612	19-32
Pregnant, or lactating patients.	Eligibility	17
Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment .	Eligibility	18
Any T4 or N1-3 or M1 breast cancer.	Eligibility	19
m1	CHEBI:34826	18-20
breast cancer	DOID:1612	21-34
Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI criteria.	Eligibility	20
severity	HP:0012824	49-57
Other serious illness or medical condition	Eligibility	21
condition	PDRO:0000129	33-42
Past or current history of neoplasm other than breast carcinoma.	Eligibility	22
history	BFO:0000182	16-23
neoplasm	HP:0002664,DOID:14566	27-35
breast carcinoma	HP:0003002,DOID:3459	47-63
Ipsilateral ductal carcinoma in-situ (DCIS) of the breast.	Eligibility	23
carcinoma	HP:0030731,DOID:305	19-28
breast	UBERON:0000310	51-57
Lobular carcinoma in-situ (LCIS) of the breast.	Eligibility	24
carcinoma	HP:0030731,DOID:305	8-17
breast	UBERON:0000310	40-46
Chronic treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose	Eligibility	25
chronic	HP:0011010	0-7
Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry.	Eligibility	26
Definite contraindications for the use of corticosteroids.	Eligibility	27
Concurrent treatment with other experimental drugs.	Eligibility	28
Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.	Eligibility	29
drug	CHEBI:23888	78-82
Concurrent treatment with any other anti-cancer therapy.	Eligibility	30
Male patients.	Eligibility	31
male	CHEBI:30780,PATO:0000384	0-4
Outcome Measurement:	Results	0
Disease-free Survival (DFS) Events	Results	1
DFS is calculated from the date of randomization until the first date of recurrence local, regional or distant, second primary tumor or death.	Results	2
second	UO:0000010	112-118
death	OAE:0000632	136-141
Time frame: 10 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Arm A: FAC	Results	5
Arm/Group Description: FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv	Results	6
5-fluorouracil	CHEBI:46345	28-42
5-fluorouracil	CHEBI:46345	76-90
doxorubicin	CHEBI:28748,BAO:0000639	44-55
doxorubicin	CHEBI:28748,BAO:0000639	148-159
cyclophosphamide	CHEBI:4026	57-73
cyclophosphamide	CHEBI:4026	176-192
day	UO:0000033	107-110
5-fluorouracil	Results	7
5-fluorouracil	CHEBI:46345	0-14
Doxorubicin	Results	8
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Results	9
cyclophosphamide	CHEBI:4026	0-16
Overall Number of Participants Analyzed: 521	Results	10
Measure Type: Number	Results	11
Unit of Measure: events  127	Results	12
Results 2:	Results	13
Arm/Group Title: Arm B: TAC	Results	14
Arm/Group Description: TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv	Results	15
doxorubicin	CHEBI:28748,BAO:0000639	39-50
doxorubicin	CHEBI:28748,BAO:0000639	137-148
cyclophosphamide	CHEBI:4026	52-68
cyclophosphamide	CHEBI:4026	165-181
day	UO:0000033	96-99
Docetaxel	Results	16
Doxorubicin	Results	17
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Results	18
cyclophosphamide	CHEBI:4026	0-16
Overall Number of Participants Analyzed: 539	Results	19
Measure Type: Number	Results	20
Unit of Measure: events  112	Results	21
Adverse Events 1:	Adverse Events	0
Total: 21/519 (4.05%)	Adverse Events	1
Anaemia 1/519 (0.19%)	Adverse Events	2
Blood bilirubin 0/519 (0.00%)	Adverse Events	3
blood	UBERON:0000178	0-5
Leukopenia 0/519 (0.00%)	Adverse Events	4
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 1/519 (0.19%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	0-11
Arrhythmia 0/519 (0.00%)	Adverse Events	6
arrhythmia	HP:0011675	0-10
Carotid artery thrombosis 1/519 (0.19%)	Adverse Events	7
carotid artery thrombosis	DOID:3410	0-25
Ear infection 0/519 (0.00%)	Adverse Events	8
ear	UBERON:0001690	0-3
Conjunctivitis 0/519 (0.00%)	Adverse Events	9
conjunctivitis	HP:0000509,DOID:6195	0-14
Abdominal pain 1/519 (0.19%)	Adverse Events	10
abdominal pain	HP:0002027	0-14
Anal fissure 0/519 (0.00%)	Adverse Events	11
anal fissure	HP:0012390,DOID:3128	0-12
Constipation 0/519 (0.00%)	Adverse Events	12
constipation	HP:0002019,DOID:2089	0-12
Diarrhoea 1/519 (0.19%)	Adverse Events	13
Adverse Events 2:	Adverse Events	14
Total: 119/532 (22.37%)	Adverse Events	15
Anaemia 1/532 (0.19%)	Adverse Events	16
Blood bilirubin 1/532 (0.19%)	Adverse Events	17
blood	UBERON:0000178	0-5
Leukopenia 1/532 (0.19%)	Adverse Events	18
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 5/532 (0.94%)	Adverse Events	19
neutropenia	HP:0001875,DOID:1227	0-11
Arrhythmia 1/532 (0.19%)	Adverse Events	20
arrhythmia	HP:0011675	0-10
Carotid artery thrombosis 0/532 (0.00%)	Adverse Events	21
carotid artery thrombosis	DOID:3410	0-25
Ear infection 1/532 (0.19%)	Adverse Events	22
ear	UBERON:0001690	0-3
Conjunctivitis 1/532 (0.19%)	Adverse Events	23
conjunctivitis	HP:0000509,DOID:6195	0-14
Abdominal pain 1/532 (0.19%)	Adverse Events	24
abdominal pain	HP:0002027	0-14
Anal fissure 1/532 (0.19%)	Adverse Events	25
anal fissure	HP:0012390,DOID:3128	0-12
Constipation 1/532 (0.19%)	Adverse Events	26
constipation	HP:0002019,DOID:2089	0-12
Diarrhoea 6/532 (1.13%)	Adverse Events	27
